Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.
idarucizumab Injection [Praxbind]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
RE-VERSE AD, a prospective multicentric cohort study, examined the effect of idarucizumab on 2 cohorts of patients anticoagulated… Expand
2017
2017
Idarucizumab is a humanized monoclonal antibody fragment engineered to specifically neutralize the effects of the oral direct… Expand
Review
2016
Review
2016
ABSTRACT The number of novel antibody therapeutics that received first marketing approvals in 2015 met expectations, with 6… Expand
2016
2016
Although clinical trials have shown that bleeding rates associated with the use of target-specific oral anticoagulant drugs are… Expand
Review
2016
Review
2016
Dabigatran, an oral anticoagulant that acts by inhibiting thrombin, was first marketed in the European Union in 2008. No antidote… Expand
2016
2016
La mise sur le marche des anticoagulants oraux directs (AOD) a multiplie les patients traites au long cours par ces molecules… Expand
Review
2015
Review
2015
Idarucizumab (Praxbind®) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific… Expand
Review
2014
Review
2014
espanolSe resenan los medicamentos evaluados y con dictamen positivo por comision de expertos de la Agencia Espanola de… Expand